Low Potential for Abuse With Extended-Release Oxycodone

An abuse liability assessment was conducted to determine the abuse potential and pharmacokinetics of extended-release vs immediate-release oxycodone.

Extended-release oxycodone (Xtampza® ER; Collegium Pharmaceuticals) had a lower abuse potential than immediate-release oxycodone, according to the results of a recent study presented at PAINWeek 2017, September 5-9, in Las Vegas, Nevada.

Researchers evaluated the abuse potential (n=52) and pharmacokinetics (n=71) of crushed and intact extended-release oxycodone compared with crushed immediate-release oxycodone.

Participants were either fed or fasted and were nondependent recreational opioid users. Peak Drug Liking on a visual analog scale was the primary end point, and Take Drug Again was the key secondary end point.

Peak Drug Liking of chewed extended-release oxycodone (fasted, mean ± SEM, 73.7±1.95; fed, 75.7±1.95) was significantly lower than immediate-release oxycodone (fasted, 86.8±1.95; P =.003 and .004, respectively). Take Drug Again scores were also lower for crushed extended-release oxycodone (fasted, mean [SD], 77.8 [18.3]; fed, 77.8 [17.7]) compared with immediate-release oxycodone (87.7 [12.9]; P <.01).

Most measures of balance of effects, positive effects (High, Good Effects), pharmacologic effects (Any Effects, Sleepy), and pupillometry were significantly lower with crushed extended-release oxycodone compared with immediate-release oxycodone.

No significant differences were noted between chewed and intact extended-release oxycodone for peak Drug Liking, peak Take Drug Again, or pharmacokinetics (peak and overall exposure).

Related Articles

In an interview with Clinical Pain Advisor, Diana Meske, PhD, presenting author of the study, concluded that “manipulation [of extended-release oxycodone] does not alter the pharmacokinetics.” While real-world studies of extended-release oxycodone use are needed, the researchers “remain optimistic that [oxycodone extended-release] will help to reduce misuse, abuse, diversion, and addiction.”

Disclosure:  Dr Meske reports being employed by Collegium Pharmaceutical.

Follow @ClinicalPainAdv


  1. Meske D, Shram M, Lagasse S, Passik S. Assessment of the oral human abuse liability and pharmacokinetics of Xtampza ER®. Presented at: PAINWeek 2017; September 5-9; Las Vegas, Nevada. Abstract 19.